Dupilumab Dupixent®
The SHIKARI® Dupilumab portfolio provides one assay for quantitative free-dupilumab measurement and two assays for anti-dupilumab antibody research in human serum or plasma. Each assay is presented according to its exact official product record.
Why Dupilumab is relevant to biological-drug monitoring research
Dupilumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Dupilumab is a fully human IgG4 monoclonal antibody directed against IL-4 receptor-α, thereby inhibiting signalling from both IL-4 and IL-13. Source ↗
Approved Indications
EMA-authorised uses span type-2 inflammatory diseases including atopic dermatitis, severe type-2 asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, eosinophilic oesophagitis, COPD with raised eosinophils and chronic spontaneous urticaria in defined age groups. EMA source ↗
Adult AD Exposure Reference
Clinical-pharmacology data for adult atopic dermatitis provide an exposure reference for the 300 mg every-two-weeks regimen:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three complementary research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free dupilumab capable of binding IL-4Rα in human serum or plasma.
Sandwich-principle ELISA for quantitative determination of free anti-dupilumab antibodies in human serum or plasma; the assay includes a confirmation-reagent procedure.
Sandwich-principle ELISA for qualitative detection of anti-dupilumab antibodies in human serum or plasma, reported as reactive or non-reactive according to assay-specific interpretation criteria.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-DUP | DUP-FD-DUP | Quantitative Drug-Level Assay | Free dupilumab | Sandwich ELISA | 96 | 2–8°C |
| SHIKARI® S-ATDUP | DUP-QNS-DUP | Quantitative Anti-Drug Antibody Assay | Free anti-dupilumab antibodies | Sandwich ELISA | 96 | 2–8°C |
| SHIKARI® S-ATDUP | DUP-QLS-DUP | Qualitative Anti-Drug Antibody Assay | Anti-dupilumab antibodies | Sandwich ELISA | 96 | 2–8°C |
Analytical specifications are summarized from the current official product records. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Which kit fits your research question?
Dupilumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Dupilumab assay and prepare regional quotation and delivery information.